2L9 Stock Overview
A precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Blueprint Medicines Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$86.80 |
| 52 Week High | US$110.90 |
| 52 Week Low | US$61.50 |
| Beta | 0.59 |
| 11 Month Change | 13.46% |
| 3 Month Change | 5.60% |
| 1 Year Change | 41.14% |
| 33 Year Change | 2.46% |
| 5 Year Change | 26.72% |
| Change since IPO | 236.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2L9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.8% | 0.8% | 0.8% |
| 1Y | 41.1% | -18.3% | 8.6% |
Return vs Industry: 2L9 exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: 2L9 exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 2L9 volatility | |
|---|---|
| 2L9 Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2L9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2L9's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 638 | Kate Haviland | www.blueprintmedicines.com |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.
Blueprint Medicines Corporation Fundamentals Summary
| 2L9 fundamental statistics | |
|---|---|
| Market cap | €5.69b |
| Earnings (TTM) | -€122.22m |
| Revenue (TTM) | €414.65m |
13.8x
P/S Ratio-46.9x
P/E RatioIs 2L9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2L9 income statement (TTM) | |
|---|---|
| Revenue | US$434.42m |
| Cost of Revenue | US$12.93m |
| Gross Profit | US$421.48m |
| Other Expenses | US$549.53m |
| Earnings | -US$128.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.02 |
| Gross Margin | 97.02% |
| Net Profit Margin | -29.48% |
| Debt/Equity Ratio | 206.9% |
How did 2L9 perform over the long term?
See historical performance and comparison